NIH Proposes Embryonic Stem Cell Research Shift Cell Lines Market
Published: 12 Mar 2026
Author: Precedence Research
The National Institutes of Health has issued a Request for Information seeking public comment on new biotechnologies that could reduce reliance on human embryos for research.
The main goal is to identify research with the given new technological developments for better effectiveness. Robustness of emerging biotechnologies, such as induced pluripotent stem cells and adult stem cells, has been approved and replaced by the use of human embryonic stem cell lines, and additional investment should be made to validate an alternate model.
NIH Guidelines for Stem Cell Research, NIH Human Embryonic Stem Cell Registry mentions review and approval of the application for new human embryonic stem cell lines. As of now, 503 human embryonic stem cell lines have been approved for NIH-supported research.
According to Toward Healthcare, the cell culture media and cell lines market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 5.96 billion in 2026 to approximately USD 13.93 billion by 2035, representing a compound annual growth rate (CAGR) of 9.9% from 2026 to 2035. While human embryonic stem cells are derived from embryos, NIH clarifies that these stem cells are not themselves embryos.
NIH Guidelines for Stem Cell Research
Secretary of Health and Human Services, Director of NIH may conduct responsible, scientifically worthy human stem cell research, including human embryonic stem cell (hESC) research, to extend permitted law. It establishes policy and procedures under which the NIH will fund such research, and helps ensure that NIH-funded research in this area is ethically responsible.
NIH modified the definition and said that human embryonic stem cells "are cells that are derived from the inner cell mass of blastocyst stage human embryos and are also capable of dividing without differentiating for a long period and are known to develop into cells and tissues of the three primary germ layers."
NIH encourages others to refrain from imposing on the transfer of research tools, sharing Biomedical Research Resources, Principles and Guidelines for Recipients of NIH Grants and Contracts.
They also require the donor(s) to receive information that the research was not intended to provide direct medical benefit to the donor(s). This resulted in research into hESCs' commercial potential.
IRB Review under the Common Rule
The NIH agrees that the IRB system of review under the Common Rule provides a complete, comprehensive framework for the review of the donation of identifiable human biological materials for research. Itincludes a full review of the informed consent process, as well as a determination of whether individuals were allowed to participate in the research and whether any undue inducements were offered to secure their participation. It is also funded with a specific set of standards reflecting currently recognised ethical principles and practices specific to embryo donation.
A recent report by Toward Healthcare highlights that the cell culture media & cell lines market has an advantage over human embryonic stem cells that are derived from the inner cell mass of the blastocyst stage human embryos, capable of dividing without differentiating for a long period.